AG-18 (Tyrphostin 23)
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407346

CAS#: 118409-57-7

Description: AG-18, also known as RG-50810; RG-50858; TX 825; Tyrphostin A23; Tyrphostin AG-18. AG-18 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 35 µM in the human epidermoid carcinoma cell line A431. AG-18 inhibits internalization of the transferrin receptor by perturbing the interaction between tyrosine motifs and the medium chain subunit of the AP-2 adaptor complex.


Chemical Structure

img
AG-18 (Tyrphostin 23)
CAS# 118409-57-7

Theoretical Analysis

MedKoo Cat#: 407346
Name: AG-18 (Tyrphostin 23)
CAS#: 118409-57-7
Chemical Formula: C10H6N2O2
Exact Mass: 186.04
Molecular Weight: 186.170
Elemental Analysis: C, 64.52; H, 3.25; N, 15.05; O, 17.19

Price and Availability

Size Price Availability Quantity
50mg USD 550 2 Weeks
100mg USD 950 2 Weeks
200mg USD 1650 2 Weeks
Bulk inquiry

Synonym: AG-18; AG 18; AG18; RG-50810; RG-50858; TX 825; Tyrphostin 23; Tyrphostin A23; Tyrphostin AG-18.

IUPAC/Chemical Name: 2-[(3,4-dihydroxyphenyl)methylene]-propanedinitrile

InChi Key: VTJXFTPMFYAJJU-UHFFFAOYSA-N

InChi Code: InChI=1S/C10H6N2O2/c11-5-8(6-12)3-7-1-2-9(13)10(14)4-7/h1-4,13-14H

SMILES Code: N#C/C(C#N)=C/C1=CC=C(O)C(O)=C1

Appearance: Light yellow solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 186.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Esther A, Iftach S, Esther P. Inhibition of Moloney murine leukemia virus replication by tyrphostins, tyrosine kinase inhibitors. FEBS Lett. 1994 Mar 14;341(1):99-103. doi: 10.1016/0014-5793(94)80248-3. PMID: 8137930.


2: Yemets A, Sheremet Y, Vissenberg K, Van Orden J, Verbelen JP, Blume YB. Effects of tyrosine kinase and phosphatase inhibitors on microtubules in Arabidopsis root cells. Cell Biol Int. 2008 Jun;32(6):630-7. doi: 10.1016/j.cellbi.2008.01.013. Epub 2008 Jan 25. PMID: 18343165.


3: Du XL, Gao Z, Lau CP, Chiu SW, Tse HF, Baumgarten CM, Li GR. Differential effects of tyrosine kinase inhibitors on volume-sensitive chloride current in human atrial myocytes: evidence for dual regulation by Src and EGFR kinases. J Gen Physiol. 2004 Apr;123(4):427-39. doi: 10.1085/jgp.200409013. Epub 2004 Mar 15. PMID: 15024039; PMCID: PMC2217456.


4: Sheremet YA, Yemets AI, Azmi A, Vissenberg K, Verbelen JP, Blume YB. Effects of tyrosine kinase and phosphatase inhibitors on mitosis progression in synchronized tobacco BY-2 cells. Tsitol Genet. 2012 Sep-Oct;46(5):3-11. PMID: 23342643.


5: Aflalo E, Iftach S, Segal S, Gazit A, Priel E. Inhibition of topoisomerase I activity by tyrphostin derivatives, protein tyrosine kinase blockers: mechanism of action. Cancer Res. 1994 Oct 1;54(19):5138-42. PMID: 7923131.


6: Seger R, Biener Y, Feinstein R, Hanoch T, Gazit A, Zick Y. Differential activation of mitogen-activated protein kinase and S6 kinase signaling pathways by 12-O-tetradecanoylphorbol-13-acetate (TPA) and insulin. Evidence for involvement of a TPA-stimulated protein-tyrosine kinase. J Biol Chem. 1995 Nov 24;270(47):28325-30. doi: 10.1074/jbc.270.47.28325. PMID: 7499332.


7: Shefler I, Seger R, Sagi-Eisenberg R. Gi-mediated activation of mitogen- activated protein kinase (MAPK) pathway by receptor mimetic basic secretagogues of connective tissue-type mast cells: bifurcation of arachidonic acid-induced release upstream of MAPK. J Pharmacol Exp Ther. 1999 Jun;289(3):1654-61. PMID: 10336565.